T he protein kinase (PK)C family of Ca 2ϩ and/or lipid-activated serine-threonine protein kinases function downstream of many signal transduction pathways. 1, 2 Approximately 10 different isozymes comprise the PKC family, which are broadly classified by their activation characteristics. The conventional PKC isozymes (PKC␣, -␤I/II, and -␥) are Ca 2ϩ -and lipid-activated, whereas the novel isozymes (, , , and ␦) and atypical isozymes ( and ) are Ca 2ϩ -independent but activated by distinct lipids. 1, 2 PKC␣ is the predominant conventional PKC isoform expressed in the mouse, rabbit, and human heart, whereas PKC␤ and PKC␥ are expressed at lower but detectable levels. [3] [4] [5] Hemodynamic pressure overload in rodents promotes translocation and presumed activation of PKC␣, -␤, -␥, -, and -during the hypertrophic phase or during later stages of heart failure. 6 -10 Human heart failure has also been associated with increased activation of conventional PKC isoforms. [11] [12] [13] Overexpression of either wild-type or a constitutively active deletion mutant of PKC␤ in a mouse heart was reported to induce cardiomyopathy 14, 15 but more recent investigation has suggested that lower levels of expression or adult onset PKC␤ activation benefits ischemic recovery, 16, 17 suggesting that PKC␤ may be slightly protective when activated. In contrast, PKC␤ Ϫ/Ϫ mice showed reduced infarct size following myocardial ischemia/reperfusion injury and greater functional recovery, similar to treatment with ruboxistaurin. 18 Thus, the function of PKC␤ as a disease modifier in the heart remains controversial and almost nothing is known about the function of PKC␥ in the heart. By comparison, transgenic mice with greater PKC␣ activity showed decreased cardiac contractility, ventricular dilation, and secondary hypertrophy, suggesting that increased PKC␣ signaling is detrimental to the heart. 19, 20 Indeed, PKC␣ Ϫ/Ϫ mice are protected from insults or genetic mutations that would otherwise induce heart failure. 19, 21 Transgenic mice with inducible expression of a dominant negative PKC␣ mutant in cardiomyocytes of the heart also showed reduced failure progression after myocardial infarction (MI) injury. 21 Inhibition of PKC␣ has been associated with protection from heart failure through at least 2 different mechanisms: one involving augmented cardiac Ca 2ϩ handling and the other involving enhanced myofilament performance. 19, 22, 23 PKC␣ phosphorylates inhibitor 1 (I-1) at a novel site, resulting in greater protein phosphatase 1 activity, leading to greater phospholamban (PLN) dephosphorylation and less activity of the sarcoplasmic reticulum Ca 2ϩ ATPase (SERCA2) pump. 19, 24 Less SERCA2 activity reduces sarcoplasmic reticulum (SR) Ca 2ϩ load, leading to reduced Ca 2ϩ release during systole, hence reduced contractility. Alternatively, PKC␣ appears to directly phosphorylate key contractile proteins, leading to reduced force production in isolated, skinned myocytes. 23 Here, we show that PKC␣ functions distinct from PKC␤ and PKC␥ in the heart and that the cardioprotective effect of the conventional PKC inhibitor ruboxistaurin is likely attributable to PKC␣ inhibition.
Materials and Methods
The PKC␣ Ϫ/Ϫ , PKC␤ Ϫ/Ϫ , and PKC␥ Ϫ/Ϫ mice have been described previously. 19, 25, 26 Transverse aortic constriction (TAC) and MI were performed as previously described by us. 27 The ␤-adrenergic receptor antagonist metoprolol (Sigma-Aldrich) was given in the drinking water at 2 g/L as previously reported. 28 Cardiac histological sections were analyzed by Metamorph as previously described. 29 Ventricular myocytes were isolated as described previously. 30 Intracellular Ca   2ϩ was measured with Fluo-4 as described previously. 31 An expanded Materials and Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

Analysis of Contractility in PKC␣-, PKC␤-, and
PKC␥-Null Mice
Here, we used genetically modified mouse models lacking PKC␣, PKC␤, and PKC␥ to gain insight into which isoform might underline propensity to heart failure on stress stimulation. Fortunately, combinatorial deleted mice were viable as adults, although PKC␣␤␥ triple nulls had reduced body weights and, hence, were not extensively studied. Western blotting from cardiac extracts with antibodies specific to PKC␣, PKC␤, and PKC␥ showed loss of each protein in the correctly targeted single-, double-, and triple-null mice ( Figure 1A ). Cardiac PKC and PKC␦ levels were also not changed in the PKC␣␤␥ gene-deleted mice (data not shown).
Given our previous results that PKC␣ Ϫ/Ϫ mice are protected from developing heart failure following pressureoverload stimulation, we were interested in examining if PKC␤ and PKC␥ functioned similarly. Given a concern of compensation, we reasoned that PKC␤␥ Ϫ/Ϫ double-null mice would be best to compare against PKC␣ Ϫ/Ϫ mice. Measurement of cardiac contractility by invasive hemodynamic assessment with a Millar pressure transducing catheter showed that PKC␣ Ϫ/Ϫ mice, but not PKC␤␥ Ϫ/Ϫ , had enhanced contractility and relaxation at baseline ( Figure 1B through  1D) . We also generated individual myocytes from adult hearts of these mice for assessment of contractile function in isolation. Cardiac myocytes from PKC␣ Ϫ/Ϫ mice, but not PKC␤␥ Ϫ/Ϫ , showed greater fractional shortening, greater contractility, and faster relaxation ( Figure 1E through 1H) . Thus, loss of PKC␣ showed greater cardiac contractile performance in vivo and in isolated adult myocytes, whereas loss of both PKC␤ and PKC␥ had no effect on these parameters.
Consistent with greater cellular contractility, adult myocytes from PKC␣ Ϫ/Ϫ hearts showed greater Ca 2ϩ transient amplitudes ( Figure 2A ). Interestingly, myocytes from PKC␤␥ null hearts had a subtle, albeit significant, reduction in the amplitude of the Ca 2ϩ transient ( Figure 2A) . We had previously shown that myocytes from PKC␣ Ϫ/Ϫ hearts had greater SR Ca 2ϩ loads because of a mechanism associated with altered PLN phosphorylation. 19 We confirmed greater SR Ca 2ϩ loads in PKC␣ Ϫ/Ϫ myocytes compared with wild-type myocytes, although PKC␤␥ Ϫ/Ϫ myocytes had a small but significant reduction in SR Ca 2ϩ load ( Figure 2B and 2C). Similarly, PKC␣ Ϫ/Ϫ mice showed enhanced PLN phosphorylation at serine 16, but not at threonine 17, which would increase SERCA2 activity and SR Ca 2ϩ load ( Figure 2E ). PKC␤␥ Ϫ/Ϫ mice showed no change in PLN serine 16 phosphorylation, although we consistently observed a small increase in threonine 17 phosphorylation ( Figure 2E ( Figure 2D ). Together, these results suggest that PKC␣ functions distinct from PKC␤ and PKC␥ in regulating Ca 2ϩ handling and contractility.
Analysis of Hypertrophy and Heart Failure in PKC␣-, PKC␤-, and PKC␥-Targeted Mice
Although not the main focus of the present study, conventional PKC isoforms have been previously implicated in regulating cardiomyocyte hypertrophy in culture. 32 Although we failed to observe any reduction in pressure overloadinduced hypertrophy in mice lacking PKC␣, and Buttrick and colleagues similarly failed to observe a reduction in PKC␤ Ϫ/Ϫ mice, the possibility of compensation among the 3 conventional isoforms remained a concern. 19, 33 We performed 2 weeks of TAC stimulation in wild-type, PKC␣ Ϫ/Ϫ PKC␤␥ Ϫ/Ϫ , and PKC␣␤␥ Ϫ/Ϫ mice, which revealed no attenuation of heart growth in any group ( Figure 3A) . Thus, loss of all conventional PKC isoforms has no attenuating affect on pressure overload-induced hypertrophy.
Longer periods of TAC stimulation can produce heart failure and even greater increases in heart weights because ventricular remodeling and chamber dilation. Here, we subjected individual PKC␣ Ϫ/Ϫ , PKC␤ Ϫ/Ϫ , PKC␥ Ϫ/Ϫ , and PKC␤␥ Ϫ/Ϫ mice to 8 weeks of TAC to analyze their susceptibility to heart failure. Although all genotypes continued to show a robust hypertrophic response after 8 weeks of TAC, the PKC␤␥ Ϫ/Ϫ mice showed significantly heavier hearts, suggesting more severe failure ( Figure 3B ). As we have previously reported, 19 assessment of fractional shortening after 8 weeks of TAC showed significant protection in PKC␣ Ϫ/Ϫ mice compared with wild-type controls ( Figure  3C ). By comparison, loss of PKC␤ or PKC␥ separately did not significantly improve or worsen fractional shortening compared with the reduction observed in wild-type controls ( Figure 3C ). However, PKC␤␥ Ϫ/Ϫ mice showed a significant worsening of ventricular performance after TAC compared with wild-type mice ( Figure 3C ). Indeed, PKC␤␥ Ϫ/Ϫ mice were the only group that showed significant increases in lung weights, indicative of pulmonary edema and more severe heart failure ( Figure 3D ). These results indicate that loss of PKC␣ protects the heart from pressure overload-associated decompensation, whereas loss of PKC␤ and -␥ renders the heart more susceptible to decompensation.
The conclusion concerning the disparity in function between PKC␣ and PKC␤ and -␥ in pressure overloadstimulated mice was further confirmed in another independent model of heart failure attributable to MI injury. The left coronary artery was permanently ligated and function was followed by echocardiography every week for 4 weeks. No difference in infarction size or scar size was noted among the groups, suggesting that any alterations in performance was likely attributable to remodeling and/or heart failure progression differences between the groups (data not shown). Consistent with past results, PKC␣ Ϫ/Ϫ mice maintained function better at weeks 2, 3, and 4, compared to wild-type mice after MI ( Figure 3E ). The reduction in fractional shortening in PKC␤ Ϫ/Ϫ or PKC␥ Ϫ/Ϫ single nulls was not different from wild-type, although PKC␤␥ Ϫ/Ϫ double-null mice showed significantly worse function at all 4 time points ( Figure 3E ). Collectively, these data suggest that PKC␣ is normally cardiomyopathic when activated in the heart during stress stimulation, whereas PKC␤ and -␥ function in a slightly protective manner when activated (see Discussion).
Ruboxistaurin Treatment in Mice During Pressure-Overload Hypertrophy and Failure
Ruboxistaurin, a previously reported PKC␤ selective antagonist, has been through late-stage clinical trials for diabetic macular edema and shown to be well tolerated. 34 Although ruboxistaurin was reported to be PKC␤ selective, 35 we determined that it was equally selective for PKC␣ (IC 50 of 14 nmol/L for PKC␣ versus 19 nmol/L for PKC␤⌱⌱). These values for ruboxistaurin were obtained from Upstate Biotechnology with their IC 50 Profiler Express system. Given that PKC␣ protein levels are also much higher than PKC␤ in the human heart, 5 it further suggests that ruboxistaurin might function predominantly through a PKC␣-dependent mechanism. Indeed, we directly measured cardiac contractility on acute ruboxistaurin infusion in mice lacking either PKC␣ or PKC␤ and -␥. We previously observed that ruboxistaurin administration to rats increased baseline contractility by 28%. 5 Here, wild-type control mice showed a small but significant increase in cardiac contractility within minutes of ruboxistaurin infusion, as did PKC␤␥ Ϫ/Ϫ mice ( Figure 4A ). However, ruboxistaurin infusion had no ability to further augment contractility in PKC␣ Ϫ/Ϫ mice ( Figure 4A ). These results indicate that ruboxistaurin enhances cardiac function specifically through effects on PKC␣ but not PKC␤ or PKC␥.
To explore the potential therapeutic ramifications of our results, we instituted a large study with nearly 100 mice (C57BL/6) treated with 2 doses of ruboxistaurin (40 and 120 mg/kg per day) administered in chow. Other groups included chow vehicle or a known agent used to treat heart failure, the ␤-adrenergic receptor antagonist metoprolol (2 g/L in drinking water) ( Figure 4B ). At 8 weeks of age, mice were subjected to TAC to induce pressure overload on the heart or a sham procedure as a control. After 1 week of TAC, all mice showed comparable pressure gradients across the aortic constrictions (data not shown). Throughout the treatment period, low-and high-dosage ruboxistaurin groups had blood levels of drug metabolite of Ϸ0 to 200 ng/mL and 400 to 1400 ng/mL, respectively (measured every 2 weeks).
Within a few weeks of TAC stimulation, vehicle-treated mice began to show mortality, such that only 6 of 15 enrolled mice were alive at week 10 ( Figure 4C ). Metoprolol and low-dose ruboxistaurin-treated mice showed slightly less lethality, whereas high-dose ruboxistaurin-treated mice showed no lethality whatsoever ( Figure 4C) . None of the mice in any of the 4 sham groups died over the 10-week treatment period. These results suggest that ruboxistaurin protected mice from lethality associated with chronic cardiac pressure-overload stimulation.
Ruboxistaurin Treatment Reduces Heart Failure After TAC
Metoprolol and low and high ruboxistaurin treatment groups all showed significantly better fractional shortening compared with vehicle-treated mice after 10 weeks of TAC ( Figure 5A ). Moreover, all groups subjected to TAC showed dilation of the left ventricle in diastole. However, the highdosage ruboxistaurin group exhibited significantly less dilation than the vehicle group ( Figure 5B ). Direct measurement of heart weights normalized to body weight also showed significantly less secondary hypertrophy associated with the failing heart in both the metoprolol and high-dose ruboxistaurin treatment groups ( Figure 5C ). However, assessment of myocyte cross-sectional areas from histological sections showed comparable hypertrophic increases, suggesting that the greater increase in organ hypertrophy in the vehicle and low-dose ruboxistaurin groups was attributable to greater remodeling ( Figure 5D ). Assessment of lung weight normalized to body weight showed significant protection in the metoprolol and high ruboxistaurin groups compared with vehicle treated mice after TAC ( Figure 5E ). Evaluation of fibrosis from ventricular histological sections stained with Masson's trichrome showed a significant degree of fibrotic material deposition in all 4 groups subjected to TAC, although the 3 drug treatment groups had significantly less ( Figure 5F ). These results collectively indicate that ruboxistaurin antagonizes the progression and severity of heart failure in mice subjected to chronic pressure-overload stimulation.
To verify that the protective effects or ruboxistaurin are attributable to PKC␣ inhibition, but not PKC␤ and -␥, we conducted a second independent study involving treatment of PKC␤␥ Ϫ/Ϫ mice subjected to TAC for 4 weeks. PKC␤␥ Ϫ/Ϫ mice were more sensitive to TAC than wild type, such that only 3 of 11 PKC␤␥ Ϫ/Ϫ mice treated with vehicle food survived 4 weeks of TAC, whereas 8 of 9 ruboxistaurin-treated (highdosage) PKC␤␥ Ϫ/Ϫ mice survived ( Figure 6A ). Separate wildtype controls were also performed, and, once again, no wild-type mice died during TAC on ruboxistaurin, but 2 of 7 vehicletreated mice died after 4 weeks ( Figure 6A ). Other indices of heart failure were also positively influenced by ruboxistaurin treatment in PKC␤␥ Ϫ/Ϫ mice, such as an improvement in fractional shortening, reductions in secondary increases in heart weight normalized to body weight, prevention of pulmonary edema, and less fibrosis ( Figure 6B through 6E) . These results indicate that ruboxistaurin influences heart failure susceptibility and death after TAC stimulation independent of PKC␤ and -␥, suggesting it benefits the heart by inhibition of PKC␣ or an entirely different kinase.
Discussion
Ruboxistaurin was initially touted as a PKC␤-selective inhibitor, although our analysis suggested equal selectively toward PKC␣ and PKC␤, and likely even PKC␥. Although this observation does not singularly implicate PKC␣ as the primary biological target for ruboxistaurin in mediating cardioprotection, a stronger case emerges when various points of datum are collectively analyzed. For example, we observed that another PKC inhibitor with selectivity for the conventional PKC isoforms, Ro-31-8220, enhanced cardiac contractility in mice, and restored ventricular function in a mouse model of dilated cardiomyopathy. 5 Similarly, a third conventional PKC isoform inhibitor, Ro-32-0432, also increased cardiac function in 2 different mouse models of heart failure, and, more importantly, it did not increase contractility in PKC␣ Ϫ/Ϫ mice. 5 Although each of these pharmacological inhibitors can have nonselective effects on other kinases, such as a known effect of ruboxistaurin on PDK1, 36 that all 3 have an identical effect on enhancing cardiac contractility and antagonizing heart failure strongly suggests that it is the commonality in blocking conventional PKC isoforms that is mechanistically important. Indeed, acute infusion of PMA, a broad-acting PKC activator, reduced cardiac contractility in wild-type but not PKC␣ Ϫ/Ϫ hearts in an ex vivo preparation. 5 Here, we extended the case even further by showing that acute infusion of ruboxistaurin augmented cardiac contractility in wild-type and PKC␤␥ Ϫ/Ϫ mice but not PKC␣ Ϫ/Ϫ mice. More importantly, ruboxistaurin protected PKC␤␥ Ϫ/Ϫ mice from heart failure and death following pressure-overload stimulation, unequivocally demonstrating that this drug is unlikely mediating cardioprotection by inhibition of PKC␤ or -␥. These results strongly suggest that the contractile and cardioprotective effects of ruboxistaurin are mediated through inhibition of PKC␣.
The various pharmacological studies discussed above are further buttressed by genetic or gene therapy-based experiments. For example, deletion of PKC␣ in mice enhanced cardiac contractility and protected from heart failure. 19 Transgene-mediated expression of dominant-negative PKC␣ in a cardiac myocyte-specific manner similarly increased contractility and protected from heart failure. 21 Moreover, adenoviral mediated gene transfer of dominant negative PKC␣ into a rat model of heart failure improved function. 5 Finally, overexpression of wild-type PKC␣ reduced cardiac function and led to heart failure. 19 By comparison, loss of PKC␤ or PKC␥, or both together, did not enhance cardiac Ca 2ϩ handling nor was it cardioprotective after injury. In fact, loss of PKC␤ and -␥ resulted in slightly lower Ca 2ϩ levels in the SR, which may be antiarrhythmic. Collectively, these various lines of evidence further implicate PKC␣ as the main target of ruboxistaurin responsible for the cardioprotective effects observed here.
PKC␣ protein levels and activity are increased in end-stage heart failure. 6, 7, 10, [11] [12] [13] 23 Although PKC␤ is also activated in heart failure, it appears to function completely differently from PKC␣ in affecting cardiac disease states. For example, PKC␤ Ϫ/Ϫ mice were not protected from pressure overload or MI-induced heart failure, similar to PKC␥ Ϫ/Ϫ mice ( Figure 3 and data not shown). PKC␤-overexpressing transgenic mice were reported to be protected from remodeling after MI, suggesting that increased PKC␤ activity could even be protective to the heart, 16 although this interpretation is somewhat incongruent with the more recent observation that PKC␤ Ϫ/Ϫ mice show less injury after acute ischemia/reperfusion. 18 PKC␤-overexpressing transgenic mice were also shown to have increased contractility and an increase in the amplitude of the Ca 2ϩ transient, 17 a phenotype that is opposite of PKC␣, which negatively regulates contractility and the amplitude of the Ca 2ϩ transient. We also observed that PKC␤␥ Ϫ/Ϫ mice faired slightly worse after pressure overload or MI injury, suggesting that PKC␤ and -␥ together might have a protective role in the heart. Thus, it is fairly certain that despite their sequence similarity and membership within the conventional subfamily, PKC␣ and PKC␤ have different biological functions in the heart.
Although deletion of PKC␤ and PKC␥ appeared to negatively impact the heart, the inhibitory effect of ruboxistaurin toward PKC␤ and PKC␥ may not be overly concerning, because inhibiting PKC␣ clearly predominates in providing protection to the heart. The protective effects of ruboxistaurin are likely mediated through a mild enhancement in cardiac contractility in a myocyte autonomous manner, as indicated by our previous work with transgenic mice and gene-deleted mice, as well as isolated hearts and adult myocytes. 5, 19, 21 However, it remains possible that the cardioprotective effects of this drug involves nonmyocytes and endocrine effects from outside the heart. Regardless of the mechanism, we believe that ruboxistaurin is an attractive agent to apply to the heart failure clinical setting, especially given its apparent safety in late phase clinical trials. 34 One final issue is how PKC␣ inhibition mechanistically attenuates heart failure. We showed previously that PKC␣ directly phosphorylates I-1, resulting in altered phosphatase 1 activity, which, in turn, regulates PLN phosphorylation. Alterations in PLN phosphorylation regulate SERCA2 function in the heart, which controls Ca 2ϩ loading and the magnitude of the Ca 2ϩ transient. 24 Here, we observed a similar enhancement in PLN phosphorylation at serine 16 in PKC␣ Ϫ/Ϫ , but not PKC␤␥ Ϫ/Ϫ , hearts. Thus, pharmacological inhibition of PKC␣ activity would function at the level of SR Ca 2ϩ handling to augment contractility. Such an enhancement in contractility through SR Ca 2ϩ loading can be beneficial to the heart in the face of insults that promote heart failure. 37 For example, deletion or inhibition of PLN dramatically increases ventricular and myocyte cellular performance and reduces or prevents cardiomyopathy in diverse models of disease. 37 Adenoviral-mediated overexpression of SERCA2 in cardiac pressure-overloaded rats also rescued heart failure and improved survival. 37 Thus, PKC␣ inhibition represents an enzymatic approach toward achieving greater contractility through an SR-dependent mechanism, which could benefit heart failure susceptibility to select insults. Alternatively, it is also possible that inhibition of PKC␣ enhances cardiac contractility through a mechanism involving the phosphorylation status of select myofilament proteins. 23 Such a mechanism could also be cardioprotective by simply enhancing the efficiency of myofilament function. Finally, it remains possible that inhibition of PKC␣ is cardioprotective through other unknown mechanisms. Regardless of the mechanism, our present data strongly suggest that PKC inhibitors, such as ruboxistaurin, should be evaluated in heart failure patients. 
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Supplemental Methods
Animal Models
The PKCα -/-, PKCβ -/-and PKCγ -/-mice have been described previously. [1] [2] [3] Transverse aortic constriction (TAC) and myocardial infarction (MI) were performed as previously described by us. 4 The β-adrenergic receptor antagonist metoprolol (Sigma-Aldrich) was given in the drinking water at 2 g/l as previously reported. 5 Mice were treated with ruboxistaurin (40 or 120 mg/kg/day) chow or the same chow composition without drug, assuming that a 25-30 g mouse consumes 4 g each day. The chow formulation was generated at Purina and was based on the #5001 rodent diet. Experiments involving animals were approved by the Institutional Animal Care and Use Committee.
Echocardiography and invasive hemodynamics
Mice were anesthetized with isoflurane, and echocardiography was performed with a carotid artery to monitor real-time heart rate, arterial and left ventricular pressures, and dP/dt max and dP/dt min using MacLab software (Mountain View, CA), as described previously. 1 In this preparation, mice were also infused with 0.2 µl/g of body weight of dimethyl sulfoxide (vehicle for ruboxistaurin) over 45 s to obtain control data, then 5 min of normalization with infusion of PBS, then a 0.2 µl/g of body weight of 2 mM ruboxistaurin was given over 45 s for experimental data collection.
Cardiac Histological Analysis
Hearts were collected at the indicated times, fixed in 10% formalin containing phosphatebuffered saline, and embedded in paraffin. Serial 5 µm heart sections from each group were analyzed. Samples were stained with H&E or Masson's trichrome. Cardiac histological sections were analyzed by Metamorph as previously described.
Western Blot Analysis
Western blotting was performed as described previously 7 was measured with Fluo-4 as described previously at 37 ºC.
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Statistics
All results are presented as means ± SEM. Paired data were evaluated by Student's t test.
A one-way ANOVA with the Bonferroni's post hoc test or repeated-measures ANOVA was used for multiple comparisons. P < 0.05 was considered statistically significant.
